Form 10-Q Tarsus Pharmaceuticals, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Tarsus Pharmaceuticals (TARS) PT Raised to $63 at BofA Securities
May 10, 2024 5:24 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $63.00 (from $60.00) while maintaining a Buy rating.
The analyst comments "Tarsus reported strong 1Q results with sales of Xdemvy (demodex blepharitis) meaningfully outperforming expectations ($25m vs. $17m cons).... More
